Top Markets
#1 Siacoin Siacoin +12.95%
#2 Cash Cat Cash Cat +10.66%
#3 0G 0G +8.47%
#4 Arbitrum Arbitrum +6.98%
#5 MarsCoin MarsCoin +6.72%
#6 Seeker Seeker +6.47%
#7 Metis Metis +5.66%
#8 Useless Coin Useless Coin +4.46%
#9 UnifAI Network UnifAI Network +4.42%
#10 Story Story +4.27%
Coin of the day
Siacoin Siacoin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Q32 Bio Inc. Q32 Bio Inc.

Q32 Bio Inc.

QTTB
Rang in aandelen #14023
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to... Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Aandeelprijs
$14.86
Laatst gesynchroniseerd: 2026-08-31
Marktkapitalisatie
$442.29M
Verandering (1 dag)
-1.13%
Verandering (1 jaar)
769.01%
Land
US
Handel Q32 Bio Inc. (QTTB)

Categorie

Healthcare
Winst voor Q32 Bio Inc. (QTTB)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Q32 Bio Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Q32 Bio Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH